At the structural level, ND Biosciences’ technologies allow reproducing the variety of conformations of misfolding proteins, including unfolded monomers, vesicle bound structures, disease-relevant oligomers with distinct conformations and morphologies, and different conformational strains of fibrillized aggregates. These advances ensure that our therapies and diagnostics will efficiently target the diversity of the disease-causing proteins and their pathologies.

One of ND Biosciences’ powerful protein engineering approaches, pioneered at the EPFL, allows generating pure protein fibrils that mimic the structural and conformational properties of fibrils purified from brains of patients suffering from Alzheimer’s disease (AD). In previous technologies utilized for drug discovery, the structure, morphology and biochemical features of generated fibrils do not reproduce that of protein aggregates typically observed in human pathology, therefore explaining the failure of these discovery programs targeting irrelevant preparations. ND Biosciences is the only company with an exclusive license to patent-pending enabling technology that allows reproducing the correct conformation of pathological Tau, one of the two main proteins implicated in the pathogenesis of AD. Importantly, this technology allows the production of relevant targets at a scale that is amenable for drug and biomarker discovery.